eConsent in Clinical Trials: More Than a Digital Signature

eConsent in Clinical Trials: More Than a Digital Signature

eConsent has been discussed in clinical trials for years, but it still feels underused compared with other patient-facing technologies like eCOA. In this episode of Digital Health Off the Record, Farrell and Edwin take a practical look at what eConsent really means, why it should be more than a PDF with an electronic signature, and how it can improve the consent experience for patients, sites and sponsors. We discuss: * Why eConsent still has not reached its full potential (00:24) * What eConsent should mean beyond a digital signature (01:17) * How eConsent can improve patient understanding and accessibility (03:45) * Why consent should be treated as a workflow, not just a document (05:17) * The hidden value of optional consent, data use and sample traceability (07:24) * Why consent forms remain too long, complex and difficult to manage (10:27) * How digital workflows can support amendments, reconsent and oversight (19:20) * Why digital consent is often held to a higher standard than paper (22:17) As with our previous discussions on eCOA and DCT-enabling technologies, the real opportunity is not simply to digitise an existing paper process. It is to rethink how clinical trial technology can make studies clearer, more accessible and easier to manage for everyone involved.

eCOA in Clinical Trials: Why Implementation Still Makes or Breaks Digital Patient Data

eCOA has been part of clinical trials for decades, but it still has not reached its full potential. In this episode of Digital Health Off the Record, Farrell and Edwin go back to basics on electronic clinical outcome assessments - what eCOA actually covers, how it differs from eDiaries and remote patient monitoring, and why it is about much more than just ePRO. They also get into the practical side of eCOA implementation, including why paper still appears in study discussions, where hidden costs and data integrity risks come from, and how better planning can remove licensing, translations, submissions and device strategy from the critical path. We cover: * What eCOA means across ePRO, ClinRO, ObsRO and PerfO [01:20] * How eCOA can support primary and secondary endpoints [03:46] * Why eDiaries and remote patient monitoring are related, but not the same thing [04:34] * The history of eCOA and the move from paper to digital [06:17] * The real cost comparison between paper and digital data capture [07:48] * “Parking lot syndrome” and why timestamps matter [09:33] * BYOD vs provisioned devices, including patient preference and reimbursement [11:10] * Sustainability considerations for study devices [15:43] * Why eCOA implementation often goes wrong [17:37] * Why licensing, translations and submissions can delay study start-up [18:10] * China-specific implementation considerations [21:00] * Accessibility, caregiver support and assisted completion [23:53] * Why paper introduces more risk than many teams realise [25:35] Ultimately, eCOA is not just a technology choice. It is an implementation, data quality and patient experience decision.

Ep 6 - GCP Meets AI: Synthetic Data, Digital Twins & Agentic Accountability

AI is moving fast, but clinical trial regulation is still catching up. In this episode of Digital Health Off the Record, Farrell and Edwin explore how AI fits within GCP today, even when it is not explicitly covered in ICH E6(R3). They break down what is usable now, what is higher risk, and how to apply existing regulatory principles as guardrails for AI adoption in clinical trials. What we cover: * EU AI Act - High-risk AI in patient safety and clinical decision making (03:30) * Quick wins - Lower-risk operational AI and workflow efficiency (05:30) * Agentic AI and the accountability challenge (07:00) * Human oversight in SAE reporting and protocol deviations (08:30) * RBQM and continuous monitoring opportunities (11:00) * Synthetic data: what it is and where it fits (12:45) * Digital twins and protocol simulation (18:30) * Reducing control arms and improving recruitment (20:30) * Data quality, model drift, and over-trust in AI outputs (22:30) Next episode, we dive into eCOA - covering implementation considerations, BYOD vs provisioned devices, translations, and licensing.

Ep 5 - ICH GCP E6(R3): Rethinking Clinical Trials

ICH GCP E6(R3) is now coming into effect across key regions like the UK and Canada and has been in Europe for months - but what does it actually mean in practice? In this episode of Digital Health Off the Record, Farrell Healion (OptiTrial) and Edwin Cohen (C&Flow) break down the shift from traditional trial thinking to a more modern, risk-based, and technology-enabled approach. We explore: * Why R3 is more than just an update - it is a rethink of how trials are designed * The real impact of Risk-Based Quality Management and focusing on what truly matters * How Digital Health Technologies are now expected, not optional * The growing role and responsibility of sites when using their own technology * What participant centricity actually looks like beyond the buzzwords We also get into the practical realities: Where does responsibility sit? How do you assess site-owned systems? And are we creating new burdens while trying to reduce others? R3 sets the direction - but the industry is still figuring out how to implement it. If you are working in clinical trials, digital health, or study operations, this is a conversation you will want to be part of.

Digital Health Off The Record Ep 4 - DCT Technologies: Beyond the Hype and Into Reality

Decentralized clinical trial technologies had their moment during COVID. But are we actually using them well today? In Episode 4, Farrell Healion and Edwin Cohen break down where DCT really stands in 2026 - cutting through the narrative of fully remote trials to focus on what actually works in practice. Because the goal was never to replace sites. It was to give patients more flexible ways to participate. We cover: - eCOA and why paper should no longer exist in 2026- eConsent - high potential, but still lagging in adoption - Wearables and connected devices - where patients are driving innovation - Telehealth as the simplest and most effective way to reduce burden - The hidden costs of paper and delayed data - Why hybrid models are the reality, not fully decentralized trials - Global challenges - from data privacy to country-specific regulations - Why most teams are not getting full value from the tech they deploy DCT is not the challenge anymore. Implementation is. If trials are meant to fit around patients’ lives, the same must be true for sites. Candid takes, no buzzwords, straight talk. Are DCT technologies reducing burden - or just shifting it somewhere else? Let us know.